|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...367368369370371372373374375376377...10671068» |
- || dexamethasone / Generic mfg., fluvoxamine / Generic mfg.
It's not about what you can google, it's about what the scientific consensus is based on the literature. The idea that there is some grand conspiracy keeping a relatively inexpensive treatment suppressed is crazy. Particularly when Fluvoxamine and dexamethasone are approved. (Twitter) - Feb 19, 2022
- | mometasone furoate nasal spray / Generic mfg.
Enrollment change, Trial withdrawal: Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED) (clinicaltrials.gov) - Feb 18, 2022
P4, N=0, Withdrawn, Sponsor: Organon and Co
N=285 --> 0 | Terminated --> Withdrawn
- | Ninlaro (ixazomib) / Takeda
Enrollment closed, Enrollment change, Trial completion date: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (clinicaltrials.gov) - Feb 18, 2022
P2, N=108, Active, not recruiting, Sponsor: Mayo Clinic
N=285 --> 0 | Terminated --> Withdrawn Recruiting --> Active, not recruiting | N=183 --> 108 | Trial completion date: Sep 2022 --> Sep 2023
- | Promacta (eltrombopag) / Novartis
Trial completion date, Combination therapy: XPAG-ITP: A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP (clinicaltrials.gov) - Feb 18, 2022
P2, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=183 --> 108 | Trial completion date: Sep 2022 --> Sep 2023 Trial completion date: Dec 2023 --> Mar 2025
- | dexamethasone / Generic mfg., midazolam hydrochloride / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Midazolam Versus Dexamethasone as an Adjuvant to Local Anesthetics in the Ultrasound Guided Hydrodissection of Median Nerve for Treatment of Carpal Tunnel Syndrome Patients (clinicaltrials.gov) - Feb 18, 2022
P=N/A, N=134, Completed, Sponsor: Minia University
Trial completion date: Dec 2023 --> Mar 2025 Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Mar 2021
- | Elzonris (tagraxofusp-erzs) / Menarini
Enrollment open: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 18, 2022
P1/2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- | Decadron (dexamethasone) / Merck (MSD), Hemady (dexamethasone tablets) / Dexcel Pharma
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Feb 17, 2022
P2, N=24, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Nov 2023 --> Nov 2024 | Initiation date: Dec 2021 --> Jul 2022 | Trial primary completion date: Nov 2023 --> Nov 2024
- ||| Buventol Easyhaler (salbutamol dry-powder inhaler) / Orion Corp, Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
Enrollment open: EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) - Feb 17, 2022
P4, N=180, Recruiting, Sponsor: Orion Corporation, Orion Pharma
Trial completion date: Nov 2023 --> Nov 2024 | Initiation date: Dec 2021 --> Jul 2022 | Trial primary completion date: Nov 2023 --> Nov 2024 Not yet recruiting --> Recruiting
- | haloperidol / Generic mfg.
New P4 trial: Haloperidol and Dexamethasone Towards Postoperative Nausea and Pain in Adult After Laparoscopy (clinicaltrials.gov) - Feb 17, 2022
P4, N=80, Completed, Sponsor: Indonesia University
- |||| budesonide / Generic mfg., mesalamine rectal enema / Generic mfg.
Clinical: @DCharabaty Ma'am What to give in a young patient of Crohn's disease with active looking terminal ileal ulcer & c/o of abdominal pain+. Will Budesonide-Controlled Release 9mg work in these?If so, for how long?how to follow up?& is there a role of Pentasa/Rowasa in such cases? (Twitter) - Feb 17, 2022
- ||||| ivermectin oral / Generic mfg., fluvoxamine / Generic mfg., fluticasone / Generic mfg.
Clinical: ACTIV-6, a Duke University placebo controlled RCT of repurposed drugs for outpatients with covid, has enrolled 3K participants, and the fluticasone arm is now complete. Fluvoxamine 50mg BID x 10 days and Ivermectin ~0.4mg/kg x 3 days arms are still open. https://t.co/AvluQcXMW7 (Twitter) - Feb 17, 2022
- | dexamethasone / Generic mfg.
Journal: Homology modelling and molecular docking study of biogenic muga silk nanoparticles as putative drug-binding system. (Pubmed Central) - Feb 17, 2022
The data was also validated using the UV-vis. spectroscopy.
- || dexamethasone / Generic mfg.
Clinical, Clinical data, Journal: Racial and Ethnic Differences and Clinical Outcomes of COVID-19 Patients Presenting to the Emergency Department. (Pubmed Central) - Feb 17, 2022
Minority patients were overrepresented among COVID-19 ED patients, and while they had similar risks of hospitalization as Whites, in-hospital mortality risk was higher. Interventions targeting upstream social determinants of health are needed to reduce racial/ethnic disparities in COVID-19.
- ||| hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
Clinical, Journal, Adverse events: Trends over time in the risk of adverse outcomes among patients with SARS-CoV-2 infection. (Pubmed Central) - Feb 17, 2022
The risk of adverse outcomes in SARS-CoV-2-positive patients decreased markedly between February and July, with subsequent stabilization from July to September. These trends were not explained by changes in measured baseline patient characteristics and may reflect changing treatment practices or viral pathogenicity.
- || dexamethasone / Generic mfg.
Clinical, Journal: Revolution of Disturbed Bregs and Bmems Lymphocytes Homeostasis in Children With Chronic ITP After High-dose Dexamethasone Rescue Therapy. (Pubmed Central) - Feb 17, 2022
HD-DXM reestablishes the normal Bregs/Bmems balance. This finding discloses possible involvement of Bregs and Bmems in the pathogenesis of pediatric ITP and provides a novel vision for immune modulation and treatment perspectives.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Systemic inflammation and oxidative stress induced by inhaled paraquat in rat improved by carvacrol, possible role of PPARγ receptors. (Pubmed Central) - Feb 17, 2022
Systemic oxidative stress and inflammation due to inhaled PQ were improved by carvacrol and pioglitazone. Higher effects of C-L+Pio-L than each one alone suggests carvacrol modulating PPAR-γ receptors.
- || dexamethasone / Generic mfg.
Clinical, Journal: Comparison of dexamethasone administration through sublingual and intramuscular routes for evaluation of pain, swelling, and trismus after impacted mandibular third molar surgery-a prospective randomized controlled study. (Pubmed Central) - Feb 17, 2022
Higher effects of C-L+Pio-L than each one alone suggests carvacrol modulating PPAR-γ receptors. This study concludes that preoperative administration of dexamethasone 8 mg through sublingual route had better efficacy than intramuscular route in controlling pain, swelling and trismus after mandibular third molar surgery.
- || Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Clinical, Journal: Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. (Pubmed Central) - Feb 17, 2022
P3
In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF)...BGF 320/18/9.6 µg and 160/18/9.6 µg significantly improved trough FEV versus GFF and FEV AUC versus BFF at week 24. The lung function benefits with both doses of BGF were maintained following 52 weeks of treatment.The reviews of this paper are available via the supplemental material section.
- || Venclexta (venetoclax) / Roche, AbbVie
P2 data, Journal, Combination therapy, IO biomarker: A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. (Pubmed Central) - Feb 17, 2022
P2
Given the limited enrollment, no clear safety or efficacy conclusions about VenPd can be drawn. Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents.
- || dexamethasone injection / Generic mfg.
Clinical, Journal: High-dose steroids in high pain responders undergoing total knee arthroplasty: a randomised double-blind trial. (Pubmed Central) - Feb 17, 2022
P4
Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents. When compared with preoperative dexamethasone 0.3 mg kg i.v., dexamethasone 1 mg kg reduced moderate-to-severe pain 24 h after TKA and improved recovery in high pain responders without apparent side-effects.
- | dexamethasone / Generic mfg.
Journal: Reactive oxygen species (ROS)-responsive nanoprobe for bioimaging and targeting therapy of osteoarthritis. (Pubmed Central) - Feb 17, 2022
This nanoprobe was fabricated by using PEG micelles modified with ROS-sensitive thioketal linkers (TK) and cartilage-targeting peptide, termed TKCP, which was then encapsulated with Dexamethasone (DEX) to form TKCP@DEX nanoparticles...Specifically targeting cartilage, TKCP@DEX could effectively respond to ROS and sustained release DEX to remarkably reduce cartilage damage in the OA joints. This smart, sensitive and endogenously activated ROS-responsive nanoprobe is promising for OA theranostics.
- || dexamethasone / Generic mfg.
Clinical, Clinical data, Retrospective data, Journal: Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infections. (Pubmed Central) - Feb 17, 2022
There was no difference in the clinical course between both groups. Because of the difference in background, corticosteroids may potentially make the clinical course of severely ill patients similar to that of mildly ill patients.
- | dexamethasone / Generic mfg.
Retrospective data, Journal: Glucocorticoid minimizes local anesthetic infusion requirement through adductor canal block and improves perioperative prosthetic joint range of motion in total knee arthroplasty. (Pubmed Central) - Feb 17, 2022
Because of the difference in background, corticosteroids may potentially make the clinical course of severely ill patients similar to that of mildly ill patients. This study suggested that single dose perineural glucocorticoid injection with DEX or DEX/MPA significantly decreased the dose of local anesthetic ropivacaine infusion required through continuous ACB for TKA while maintaining comparable level of pain score and opioid consumption, and significantly more patients were discharged home.
- | Darzalex IV (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
Journal: Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. (Pubmed Central) - Feb 17, 2022
Despite the limitations of our case series, we described the first UK real-world report of IsaPomDex outcomes in myeloma patients with a prior exposure to daratumumab. Large prospective studies are required to further evaluate myeloma outcomes in this setting.
- | dexamethasone / Generic mfg.
Journal: Efficacy of awake prone positioning for severe illness coronavirus disease 2019 patients: a propensity score-adjusted cohort study. (Pubmed Central) - Feb 17, 2022
Length of stay in the severe COVID-19 patient unit did not differ significantly (adjusted percentage difference, -24.4%; 95% confidence interval, -56.3% to 30.8%; P = 0.32). Awake PP could be correlated with intubation rate in patients with COVID-19 who are receiving remdesivir, dexamethasone, and anticoagulant therapy.
- | prednisone / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Trial termination, Combination therapy: The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. (clinicaltrials.gov) - Feb 17, 2022
P=N/A, N=6, Terminated, Sponsor: Wenhu Liu
Awake PP could be correlated with intubation rate in patients with COVID-19 who are receiving remdesivir, dexamethasone, and anticoagulant therapy. N=166 --> 6 | Not yet recruiting --> Terminated; the clinical significance is little
- ||||||| Xhance (fluticasone propionate intranasal spray) / OptiNose
Trial completion: Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps (clinicaltrials.gov) - Feb 17, 2022
P3, N=332, Completed, Sponsor: Optinose US Inc.
N=166 --> 6 | Not yet recruiting --> Terminated; the clinical significance is little Active, not recruiting --> Completed
- | dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date: Dexamethasone for Post Traumatic Headache (clinicaltrials.gov) - Feb 17, 2022
P4, N=162, Recruiting, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Clinical: It had interactions with 2 of my maintenance medications I just stopped my advair for 5 days and my amlodipine dose was decreased for those 5 days. Certainly beat another vacation to the ICU in my opinion (Twitter) - Feb 17, 2022
- | New P3 trial: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer (clinicaltrials.gov) - Feb 17, 2022
P3, N=75, Recruiting, Sponsor: Shi Yanxia
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 17, 2022
P2, N=30, Recruiting, Sponsor: National Cancer Center, Korea
- || Opdivo (nivolumab) / BMS
Trial completion date, Monotherapy, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2022
P1/2, N=316, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Trial completion date: Jan 2022 --> Nov 2022
- | triamcinolone acetonide / Generic mfg.
Journal: Combined intralesional triamcinolone acetonide and platelet rich plasma versus intralesional triamcinolone acetonide alone in treatment of keloids. (Pubmed Central) - Feb 16, 2022
Both groups showed significant improvement in all parameters of VSS and VRS in comparison with baseline. Significantly better improvement in height, pigmentation, pliability and overall VSS was detected in patients of group A. A significantly higher incidence of post-TA atrophy and hypopigmentation was observed in group B. Combining intralesional PRP with TA could yield cosmetically better outcomes in keloid treatment with lower incidence of TA-induced side effects especially atrophy and hypopigmentation.
- || dexamethasone injection / Generic mfg.
Clinical, Journal: Dengue and Plasmodium falciparum Coinfection With Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Boy: A Clinical Conundrum. (Pubmed Central) - Feb 16, 2022
The child gradually improved and was discharged with normal counts on follow-up over the next 3 months. This article emphasizes on the importance of high degree of suspicion, early workup, and initiation of treatment for HLH for a better outcome.
- | dexamethasone / Generic mfg.
Journal: Effects of corticosteroids and platelet-rich plasma on synoviocytes in IL-1ß-induced inflammatory condition. (Pubmed Central) - Feb 16, 2022
Corticosteroid regulated the inflammation and synovial homeostasis. When PRP and the corticosteroid were used together, it exhibited synergistic effects on synoviocytes by regulating the parts that were not controlled by corticosteroid alone while not interfering with the effects of the corticosteroid in an inflammatory condition.
- || mometasone furoate / Generic mfg.
Clinical, Journal: Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis. (Pubmed Central) - Feb 16, 2022
We collected punch biopsies and tape strips from healthy controls (n = 6) and subjects with AD (n = 12) at baseline and after 2 weeks of topical treatment with mometasone furoate 0.1% cream...Treatment with topical corticosteroid led to a significant decrease in mRNA levels for IL-13 and IL-4R but no significant differences in cytokine protein levels measured in tape strips. Finally, we found no significant correlations between cytokine levels in tape strips and mRNA levels in skin biopsies.
- || salmeterol/fluticasone easyhaler / Orion Corp
Clinical, Journal: A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler in routine clinical practice. (Pubmed Central) - Feb 16, 2022
The results from this prospective real-life clinical study indicate better or at least similar treatment control of asthma and COPD after switching to S/F Easyhaler from another S/F inhaler. This study also shows that S/F Easyhaler was favored by the patients and that it is easy to teach, learn and use in a real-life setting.The reviews of this paper are available via the supplemental material section.
- | dexamethasone / Generic mfg.
Journal, IO biomarker: Artemisinin Reverses Glucocorticoid-Induced Injury in Bone Marrow-Derived Mesenchymal Stem Cells through Regulation of ERK1/2-CREB Signaling Pathway. (Pubmed Central) - Feb 16, 2022
At relatively low concentrations, artemisinin treatment improved BMSC survival by promoting a decline of reactive oxygen species (ROS) production that correlated with the decrease of caspase-3 activation, LDH release, mitochondrial membrane potential (Δψm) loss, and apoptosis induced by dexamethasone (DEXA)...PD98059, the specific inhibitor of the ERK1/2 pathway, blocked ERK1/2 phosphorylation and artemisinin protection...In addition, we found that the expression of antiapoptotic protein B-cell lymphoma 2 protein (BCL-2) was also upregulated by artemisinin. These studies demonstrate the therapeutic potential of artemisinin in the survival improvement of BMSCs exposed to glucocorticoid-induced apoptosis and suggest that artemisinin-mediated protection may occur via the activation of ERK1/2-CREB signaling pathway.
- | dexamethasone / Generic mfg.
Journal: Oxygen and Steroids Affect the Regulatory Role of Natriuretic Peptide Receptor-C on Surfactant Secretion by Type II Cells. (Pubmed Central) - Feb 16, 2022
DEX markedly reduced AEC2 NPR-C expression, and pregnant ewes treated with betamethasone showed reduced ANP in fetal sheep lung fluid. These data suggest that elevated O downregulates AEC2 NPR-C, and that steroid-mediated NPR-C downregulation in neonatal lungs may provide a novel mechanism for their effect on perinatal surfactant production.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Effects of Alendronate and Dexamethasone on Osteoclast Gene Expression and Bone Resorption in Mouse Marrow Cultures. (Pubmed Central) - Feb 16, 2022
DEX treatment increased the gene expression of RANKL and reduced OPG. The treatment with ALN reduced the depth of the resorption pits, but their inhibitory effect was less effective when administered with DEX.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, Adverse events, PD(L)-1 Biomarker, IO biomarker: A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. (Pubmed Central) - Feb 16, 2022
Increases in CTLA-4 and TIM-3 expression in CD4+ T cells (not CD8+), as well as an increase in Th17 cells, may reflect asthma-related inflammation activity. Immune-related adverse events during immune checkpoint inhibitor administration may be predictive markers of antitumor efficacy.
- || Maxidex (dexamethasone eye drops, suspension) / Novartis
PK/PD data, Preclinical, Journal: Topical Pharmacokinetics of Dexamethasone Suspensions in the Rabbit Eye: Bioavailability Comparison. (Pubmed Central) - Feb 16, 2022
This study provides for the first-time comprehensive and quantitative ocular pharmacokinetic parameters (including absolute bioavailability) for topically instilled dexamethasone suspensions. Furthermore, the new intracameral pharmacokinetic parameters allow rational and quantitative basis for the design of improved ocular dexamethasone delivery systems.
- | dexamethasone / Generic mfg.
Journal: Impact of Supramolecular Interactions on Delivery of Dexamethasone from a Physical Network of Gelatin/ZnHAp Composite Scaffold. (Pubmed Central) - Feb 16, 2022
In-vitro drug release studies confirmed sustained release of DEX over a period of 12 days for GelUPy/nZnHApUPy composites with no remarkable initial burst compared to that of the pure GelUPy. Overall, our data suggests that the DEX carrying supramolecular nanocomposite can be used as an osteogenic hydrogel scaffold for bone tissue engineering applications.
- | methylprednisolone sodium succinate / Generic mfg.
Journal: Multisystem inflammatory syndrome in an adult (MIS-A) due to SARS-CoV-2 infection presenting to a South African hospital. (Pubmed Central) - Feb 16, 2022
Treatment with intravenous methylprednisolone and intravenous immunoglobulin was initiated with rapid improvement in clinical condition and inflammatory markers. She has since made a full recovery with normal echocardiogram 8 months later.
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial initiation date, Real-world evidence, Real-world: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® (clinicaltrials.gov) - Feb 16, 2022
P=N/A, N=660, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
She has since made a full recovery with normal echocardiogram 8 months later. Initiation date: Jan 2022 --> May 2022
- | Matulane (procarbazine hydrochloride) / Leadiant Biosciences
Journal: Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received. (Pubmed Central) - Feb 16, 2022
The main chemotherapy regimens applied were: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP (EB; bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, prednisone)...Cumulative hydrocortisone equivalent doses >3400 mg/m correlated with significant BMD reduction...Its persistence is associated with age ≥30 years and EB treatment. Reduction of cumulative steroid doses and switch to non-gonadotoxic drugs should be considered.
- | dexamethasone / Generic mfg.
Journal: Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management. (Pubmed Central) - Feb 16, 2022
The combination of FGR and intracavitary thermotherapy with SPION provides a new treatment option for improving local tumor control in recurrent HGG. The development of cerebral edema is a major issue requiring further refinements of the treatment protocol.
- |||| Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Feb 16, 2022
P3, N=551, Active, not recruiting, Sponsor: Bayer
The development of cerebral edema is a major issue requiring further refinements of the treatment protocol. Trial primary completion date: Apr 2022 --> Feb 2023
- | Trial completion: Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Orchiopexy Repair (clinicaltrials.gov) - Feb 16, 2022
P=N/A, N=90, Completed, Sponsor: Alberta Children's Hospital
Trial primary completion date: Apr 2022 --> Feb 2023 Recruiting --> Completed